Immuron Overview

  • Status
  • Public
  • Employees
  • 4
Employees
  • Stock Symbol
  • IMC
Stock Symbol
  • Share Price
  • $0.07
  • (As of Tuesday Closing)

Immuron General Information

Description

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Contact Information

Formerly Known As
Anadis
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
ASX
Primary Office
  • Building 10
  • 25-37 Chapman Street
  • Blackburn North, Victoria 3131
  • Australia
+61 (03) 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immuron Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.07 $0.07 $0.07 - $0.13 $16.5M 228M 279K -$0.01

Immuron Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 30-Jun-2021 FY 2020 30-Jun-2020 FY 2019 30-Jun-2019
EV (2,330) 6,712 28,397 10,765
Revenue 267 109 1,687 1,707
EBITDA (3,348) (6,215) (1,917) (3,326)
Net Income (3,343) (6,251) (1,961) (3,329)
Total Assets 18,396 20,326 4,262 5,996
Total Debt 164 15 42 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immuron Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immuron‘s full profile, request access.

Request a free trial

Immuron Patents

Immuron Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2986316-A1 Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease Pending 19-Apr-2013 00000000000
CA-2909636-A1 Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease Pending 19-Apr-2013 00000000000
US-20160083457-A1 Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease Granted 19-Apr-2013 00000000000
AU-2014253685-A1 Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease Granted 19-Apr-2013 00000000000
AU-2014253685-B2 Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease Active 19-Apr-2013 C07K16/1282 0
To view Immuron’s complete patent history, request access »

Immuron Executive Team (7)

Name Title Board Seat Contact Info
Jerry Kanellos Ph.D Chief Executive Officer & Chief Operating Officer, Operations
Phillip Hains Chief Financial Officer, Finance & Secretary, Administration
Peter Anastastiou Executive Vice Chairman
You’re viewing 3 of 7 executive team members. Get the full list »

Immuron Board Members (5)

Name Representing Role Since
00000 00000000000 Immuron Executive Vice Chairman 000 0000
0000 00000000000 Immuron Board Member 000 0000
00000 00000 00.0 Immuron Chairman 000 0000
You’re viewing 3 of 5 board members. Get the full list »

Immuron Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial